• Archives of Pharmacal Research
• /
• 제19권2호
• /
• pp.168-170
• /
• 1996

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제5권1호
• /
• pp.83-92
• /
• 1994

본 연구의 목적은, 선택적 serotonin 재흡수 차단제(selective serotonin re-uptake inhibitors : SSRI)로서 불안증상을 동반한 비정신병적 우울증에 효과적인 치료제로 알려지고 있는 paroxetine의 항우울 및 항불안 효과를 검증하고, 성별 및 연령별로 효과의 차이를 파악하는 것이다. 이를 위해 8~55세 사이의 우울신경증 환자 232명을 대상으로 paroxetine과 위약을 이중맹 교차방식으로 투여한 후, 우울 및 불안 증상의 호전도를 Hamilton Depression Scale(HDS)과 Hamilton Anxeity Scale(HAS)로 측정하여 다음과 같은 결과를 얻었다. 1) HDS로 측정된 우울증상에 대해, 성별 및 연령별로 구분된 8개 대상군에서 모두 paroxetine이 위약에 비해 통계적으로 유의하게 높은 호전 효과를 보였다. 2) HAS로 측정된 불안증상에 대해서도, 성별 및 연령별로 구분된 8개 대상군에서 모두 paroxetine이 위약에 비해 통계적으로 유의하게 높은 호전 효과를 보였다. 3) 위약과 비교시, paroxetine의 항우울 효과는 소아 ${\cdot}$ 청소년 여자 환자군에서 가장 두드러졌고, 항불안 효과는 남 ${\cdot}$ 녀 소아 환자군과 35세 이하의 성인 여자 환자군에서 가장 높은 경향을 보였다. 4) 부작용으로는, 전체 232례 중 3례에서 paroxetine 투여 후 경미한 소화불량 및 복통증상을 나타내었으나, 3례 모두 약물의 감량이나 투여중단 없이 회복이 가능했다. 이상의 결과에서 paroxetine은 소아 ${\cdot}$ 청소년 및 성인 우울신경증 환자에서 2주 이내에 위약보다 유의하게 우수한 항우울 및 항불안 효과를 나타내는 것을 알 수 있었다. 향후 보다 장기간의 치료실험을 통하여 이러한 효과의 장기간 지속성에 대한 검증이 필요한 것이다.

• Bulletin of the Korean Chemical Society
• /
• 제33권8호
• /
• pp.2597-2602
• /
• 2012

Novel 1,4-substituted piperazine derivatives 5, Series A and B were designed by fragment analysis and molecular modification of 4 selected piperazine-containing compounds which possess antidepressant activity. We synthesized new 39 analogues of Series A and 10 compounds of Series B, respectively. The antidepressant screening against DA, NE, and serotonin neurotransmitter uptake inhibition was carried out using the Neurotransmitter Transporter Uptake Assay Kit. The compounds in Series B showed relatively higher reuptake inhibitory activity for SERT, NET, and DAT than those in Series A. The length of spacer between the central piperazine core and the terminal phenyl ring substituted at the piperazine ring in Series B seems to exert an important role in the activity.

• 수면정신생리
• /
• 제17권1호
• /
• pp.5-10
• /
• 2010

Restless legs syndrome (RLS) is a common sensorimotor disorder that is characterized by an urge to move the legs and peculiar, unpleasant sensations deep in the legs and its prevalence in the general population is between 3.2% and 15%. RLS significantly impairs patients' lives, often by severely disrupting sleep. However, both clinicians and patients under-recognize the RLS. RLS phenotypes include an idiopathic form and secondary form that is usually resulted from various causative conditions. The pathophysiology of RLS may be related with the dopaminergic system, which is closely linked to a number of psychotropic medications, including antidepressant and antipsychotics. Several antidepressants and antipsychotics have been shown to induce or exacerbate RLS. We need pay attention to the fact that commonly prescribed medications can be the cause of RLS.

• 생물정신의학
• /
• 제23권1호
• /
• pp.1-11
• /
• 2016

Development of various antidepressants such as monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and noradrenergic and specific serotonergic antidepressant has led to a tremendous progression of pharmaceutical treatment for depression, but still there are some limitations of current antidepressants, such as treatment-resistant depression and delayed onset of antidepressants. The pathogenesis of depression is unclear because depression is a heterogeneous disease state, and the mechanisms of antidepressants remain uncertain as well. Nevertheless, in an attempt to develop novel antidepressants, some trials have been conducted based on the potential biological mechanism discovered in the numerous research results. This review will provide information about the potential novel antidepressants and the current states of clinical studies using them. In particular, some potential novel antidepressants anti-inflammatory agents, antioxidants, anticholinergics, modulators of Hypothalamic Pituitary Adrenal Axis, glutamate, and opioid systems, as well as some neuropeptides such as susbstance P, neuropeptide Y, and galanin will be discussed.

• Natural Product Sciences
• /
• 제20권4호
• /
• pp.258-261
• /
• 2014

Antidepressant miquelianin (quercetin 3-O-glucuronide) was isolated from the leaves of Rubus craetaegifolius (Rosaceae) and identified by physical and spectroscopic data. Miquelianin was quantitatively analyzed in the leaves, mature and premature fruits of Korean wild R. craetagifolius, R. pungens var. oldhami, R. coreanus, and R. parvifolius by HPLC. The contents of miquelianin was highest in the mature fruit of R. crataegifolius ($16.29{\pm}0.79mg/g$); however, the content of kaempferol 3-O-glucuronide was $33.88{\pm}7.68mg/g$. These results suggest that the mature fruit of R. crataegifolius would be beneficial for treating depression or stress as a functional food with its sweet taste.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제19권2호
• /
• pp.83-88
• /
• 2008

Antidepressants, in particular selective serotonin reuptake inhibitors (SSRIs), are one of the most commonly used classes of psychotropic drugs for treating children and adolescents. The US Food and Drug Administration has issued a black box warning concerning the increased risks of suicidal ideation and behavior associated with antidepressant treatment in children and adolescents. The aim of this review is to assess the risks and benefits of antidepressants in the treatment of child and adolescent psychiatric disorders.

• 생물정신의학
• /
• 제7권1호
• /
• pp.21-33
• /
• 2000

As the clinical practice of using more than one drug at a time increase, the clinician is faced with ever-increasing number of potential drug interactions. Although many interactions have little clinical significances, some may interfere with treatment or even be life-threatening. This review provides a better understanding of drug-drug interactions often encountered in pharmacotherapy of depression. Drug interactions can be grouped into two principal subdivisions : pharmacokinetic and pharmacodynamic. These subgroups serve to focus attention on possible sites of interaction as a drug moves from the site of administration and absorption to its site of action. Pharmacokinetic processes are those that include transport to and from the receptor site and consist of absorption, distribution on body tissue, plasma protein binding, metabolism, and excretion. Pharmacodynamic interactions occur at biologically active sites. In this review, emphasis is placed on antidepressant medications, how they are metabolized by the P450 system, and how they alter the metabolism of other drugs. When prescribing antidepressant medications, the clinician must consider the drug-drug interactions that are potentially problematic.

• 생물정신의학
• /
• 제18권4호
• /
• pp.169-175
• /
• 2011

Stress, a risk factor of major depression induces cytokine mediated inflammation and decreased neurogenesis. In patients with major depression, significant increases of pro-inflammatory cytokines have been consistently reported. The pro-inflammatory cytokines can stimulate the hypothalamic-pituitary-adrenal (HPA) axis to release glucocorticoids. In the brain, microglia and play a role of immune activation in response to stress. Increased pro-inflammatory cytokine play a role in restricting neurogenesis in the brain. Although neurogenesis may not be essential for the development of depression, it may be required for clinically effective antidepressant treatment. Hence, stimulation of neurogenesis is regarded as a promising strategy for new antidepressant targets. This review introduces changes in neurotransmitter, cytokine and neurogenesis in major depression and explores the possible relationship between pro-inflammatory cytokines and neurogenesis related to stress in major depression.

• 생물정신의학
• /
• 제17권1호
• /
• pp.5-14
• /
• 2010

Depressive disorder is a chronic disabling condition with recurrent episodes. Medication noncompliance is a significant problem for effective management of depressive disorder. However, compliance with antidepressant medication is poor. There are difficulties in assessing compliance accurately. Various methods for assessing compliance are in use. A patient's compliance with antidepressant may be affected by many factors including the clinical characteristics of depression, pharmacologic properties of antidepressants, patients' characteristics, accessibility treatment, and doctor-patient relationships. For enhancing the treatment compliance, psychotherapeutic considerations in patient-therapist relationship are needed.